JP2010527917A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527917A5
JP2010527917A5 JP2010506715A JP2010506715A JP2010527917A5 JP 2010527917 A5 JP2010527917 A5 JP 2010527917A5 JP 2010506715 A JP2010506715 A JP 2010506715A JP 2010506715 A JP2010506715 A JP 2010506715A JP 2010527917 A5 JP2010527917 A5 JP 2010527917A5
Authority
JP
Japan
Prior art keywords
ifnα
expression profile
inducible
patient
marker expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010506715A
Other languages
English (en)
Japanese (ja)
Other versions
JP5411129B2 (ja
JP2010527917A (ja
Filing date
Publication date
Priority claimed from PCT/US2007/024947 external-priority patent/WO2008070137A2/en
Application filed filed Critical
Priority claimed from PCT/US2008/062646 external-priority patent/WO2008137838A2/en
Publication of JP2010527917A publication Critical patent/JP2010527917A/ja
Publication of JP2010527917A5 publication Critical patent/JP2010527917A5/ja
Application granted granted Critical
Publication of JP5411129B2 publication Critical patent/JP5411129B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010506715A 2007-05-03 2008-05-05 インターフェロンα誘導性薬力学的マーカー Expired - Fee Related JP5411129B2 (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US92421907P 2007-05-03 2007-05-03
US92422007P 2007-05-03 2007-05-03
US60/924,220 2007-05-03
US60/924,219 2007-05-03
US92458407P 2007-05-21 2007-05-21
US60/924,584 2007-05-21
US96018707P 2007-09-19 2007-09-19
US60/960,187 2007-09-19
US99617607P 2007-11-05 2007-11-05
US99617407P 2007-11-05 2007-11-05
US60/996,176 2007-11-05
US60/996,174 2007-11-05
US99621907P 2007-11-06 2007-11-06
US60/996,219 2007-11-06
US99682007P 2007-12-06 2007-12-06
USPCT/US2007/024947 2007-12-06
PCT/US2007/024947 WO2008070137A2 (en) 2006-12-06 2007-12-06 Interferon alpha-induced pharmacodynamic markers
US60/996,820 2007-12-06
USPCT/US2007/024941 2007-12-06
PCT/US2007/024941 WO2008070135A2 (en) 2006-12-06 2007-12-06 Methods of treating systemic lupus erythematosus
US696308P 2008-02-08 2008-02-08
US61/006,963 2008-02-08
PCT/US2008/062646 WO2008137838A2 (en) 2007-05-03 2008-05-05 Interferon alpha-induced pharmacodynamic markers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013230753A Division JP2014064577A (ja) 2007-05-03 2013-11-07 インターフェロンα誘導性薬力学的マーカー

Publications (3)

Publication Number Publication Date
JP2010527917A JP2010527917A (ja) 2010-08-19
JP2010527917A5 true JP2010527917A5 (https=) 2011-06-16
JP5411129B2 JP5411129B2 (ja) 2014-02-12

Family

ID=39944226

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010506714A Withdrawn JP2010526107A (ja) 2007-05-03 2008-05-05 自己免疫疾患の自己抗体マーカー
JP2010506715A Expired - Fee Related JP5411129B2 (ja) 2007-05-03 2008-05-05 インターフェロンα誘導性薬力学的マーカー
JP2013230753A Pending JP2014064577A (ja) 2007-05-03 2013-11-07 インターフェロンα誘導性薬力学的マーカー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010506714A Withdrawn JP2010526107A (ja) 2007-05-03 2008-05-05 自己免疫疾患の自己抗体マーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013230753A Pending JP2014064577A (ja) 2007-05-03 2013-11-07 インターフェロンα誘導性薬力学的マーカー

Country Status (6)

Country Link
US (2) US9181345B2 (https=)
EP (2) EP2068924A4 (https=)
JP (3) JP2010526107A (https=)
AU (2) AU2008247395A1 (https=)
CA (2) CA2686861A1 (https=)
WO (2) WO2008137838A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
EP2620770B1 (en) * 2010-09-22 2017-04-26 National University Corporation Chiba University Novel testing method for angiitis
GB201017520D0 (en) * 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
KR20140048877A (ko) * 2011-04-26 2014-04-24 제넨테크, 인크. 자가면역 질환의 치료를 위한 조성물 및 방법
AU2013204776A1 (en) * 2011-04-26 2013-05-09 Genentech, Inc. Compositions and method for treating autoimmune diseases
EP2923205B1 (en) * 2012-11-23 2019-05-15 Baerlecken, Niklas Analysis for adult-onset still's disease
WO2014093934A1 (en) * 2012-12-14 2014-06-19 Mindera Corporation Methods and devices for detection and acquisition of biomarkers
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
WO2015085172A2 (en) * 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CA3073537A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022512796A (ja) 2018-10-26 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド Ｉ型インターフェロンシグネチャー及び使用方法
CN110747190B (zh) * 2019-11-27 2021-03-09 浙江华睿生物技术有限公司 一种马来酸水合酶突变体及其应用
WO2025062016A2 (en) * 2023-09-22 2025-03-27 Merck Patent Gmbh Biomarkers for tlr inhibitor treatment
WO2026004792A1 (ja) * 2024-06-24 2026-01-02 キヤノンメディカルダイアグノスティックス株式会社 細胞性免疫応答活性を測定する方法及びそのためのキット

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8303165D0 (en) 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
DE3306060A1 (de) 1983-02-22 1984-08-23 Boehringer Ingelheim International GmbH, 6507 Ingelheim Neue immunglobulin-produzierende hybridzellinien, deren verwendung und verfahren zu deren herstellung
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
FR2692168B1 (fr) 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
CA2303268A1 (en) 1997-06-13 1998-12-17 Scott Walsh Therapeutic nanospheres
US20050008683A1 (en) * 2000-06-29 2005-01-13 Becton Dickinson And Company Method for delivering interferons to the intradermal compartment
US20040265874A1 (en) * 2000-10-17 2004-12-30 Bio-Rad Laboratories, Inc. Pattern recognition method for diagnosis of systemic autoimmune diseases
EP1351707B9 (en) * 2001-01-09 2012-01-25 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
CA2467647A1 (en) * 2001-11-30 2003-06-05 Innogenetics N.V. Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma
DK1569696T3 (da) * 2002-11-21 2010-11-15 Bayhill Therapeutics Inc Fremgangsmåder og immunmodulatoriske nukleinsyrepræparater til forebyggelse og behandling af sygdomme
CA2537273A1 (en) * 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
KR101225299B1 (ko) * 2003-12-10 2013-01-24 메다렉스, 인코포레이티드 인터페론 알파 항체 및 그의 용도
CN101155831B (zh) * 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
US20070117105A1 (en) * 2005-05-12 2007-05-24 Crow Mary K Interferon assay
US20070065844A1 (en) * 2005-06-08 2007-03-22 Massachusetts Institute Of Technology Solution-based methods for RNA expression profiling
DK2327792T3 (da) * 2005-08-05 2014-01-13 Genentech Inc Fremgangsmåder og sammensætninger til påvisning af autoimmunsygdomme
US7608395B2 (en) * 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
WO2007142667A2 (en) * 2005-10-13 2007-12-13 Human Genome Sciences, Inc. Treatment of patients with autoantibody positive disease
EP2712930A3 (en) * 2006-12-06 2014-04-23 MedImmune, LLC Interferon alpha-induced pharmacodynamic markers
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic

Similar Documents

Publication Publication Date Title
JP2010527917A5 (https=)
JP2010512315A5 (https=)
Powell et al. Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response
Sypabekova et al. Electrochemical aptasensor using optimized surface chemistry for the detection of Mycobacterium tuberculosis secreted protein MPT64 in human serum
RU2014127178A (ru) Фармакодинамические маркеры, индуцированные интерфероном альфа2009125616 06.12.2006
Camela et al. Towards personalized medicine in psoriasis: current progress
An et al. From moderately severe to severe hypertriglyceridemia induced acute pancreatitis: circulating miRNAs play role as potential biomarkers
MX2014004712A (es) Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal.
Burrell et al. Re-evaluating clonal dominance in cancer evolution
NZ590988A (en) Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
Qasem et al. Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
Flanagan et al. The Candida albicans TOR-activating GTPases Gtr1 and Rhb1 coregulate starvation responses and biofilm formation
JP2013178260A5 (https=)
Glatt et al. Elongator: transcriptional or translational regulator?
Liu et al. Functional effect of polymorphisms in the promoter of TNFAIP3 (A20) in acute pancreatitis in the Han Chinese population
Kadasah et al. Tumor necrosis factor-α and-β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia
Hao et al. Multi-omics in allergic rhinitis: mechanism dissection and precision medicine
Sun et al. Downregulation of microRNA‐101‐3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9
Mahmood et al. The pncA gene mutations of Mycobacterium tuberculosis in multidrug‐resistant tuberculosis
Safarinejad Analysis of association between the 5‐HTTLPR and STin2 polymorphisms in the serotonin‐transporter gene and clinical response to a selective serotonin reuptake inhibitor (sertraline) in patients with premature ejaculation
JP2015502137A5 (https=)
CN103820545B (zh) 用于检测人abcg2基因突变的探针、引物及试剂盒
Moraes Holst et al. Downregulated mucosal autophagy, alpha kinase-1 and IL-17 signaling pathways in active and quiescent ulcerative colitis
Chen et al. Loss of BCAT1 expression is a sensitive marker for IDH-mutant diffuse glioma
Troudet et al. Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses